Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>CVS Health investors saw a significant turnaround as the company delivered better-than-expected quarterly earnings, fueling a sharp 14.8% rise in stock price—the largest one-day gain since 2008.</li><li>This surge follows a tumultuous 2024 when the stock fell over 40% due to challenges across its core businesses, including rising medical costs in its insurance segment, regulatory scrutiny on its pharmacy-benefit manager, and financial pressures on its retail pharmacy chain.</li><li>However, with a new CEO at the helm, the company is focused on restoring investor confidence and executing a strategic recovery plan.</li></ul>

CVS Health investors saw a significant turnaround as the company delivered better-than-expected quarterly earnings, fueling a sharp 14.8% rise in stock price—the largest one-day gain since 2008.This surge follows a tumultuous 2024 when the stock fell over 40% due to challenges across its core businesses, including rising medical costs in its insurance segment, regulatory scrutiny on its pharmacy-benefit manager, and financial pressures on its retail pharmacy chain.However, with a new CEO at the helm, the company is focused on restoring investor confidence and executing a strategic recovery plan.

CVS Health: $97.7 Billion Revenue and a New CEO – Can It Overcome Industry Challenges?

Cvs Health Corp

CVS Health: $97.7 Billion Revenue and a New CEO – Can It Overcome Industry Challenges?